|
... also wenn das nun keine Hammer-News sind ?! Bin davon überzeugt, daß Geron heute mind. 60% zulegen wird. ---- Geron Receives U.S. Patent Covering Use of Telomerase Inhibitors in Patients Geron Receives U.S. Patent Covering Use of Telomerase Inhibitors in Patients BW5329 APR 15,2003 4:32 PACIFIC 07:32 EASTERN ( BW)(CA-GERON)(GERN) Geron Receives U.S. Patent Covering Use ofTelomerase Inhibitors in Patients Business Editors/Health/Medical Writers BIOWIRE2K MENLO PARK, Calif.--(BUSINESS WIRE)--April 15, 2003--GeronCorporation (Nasdaq:GERN) announced today that it has been grantedU.S. Patent No. 6,548,298, by the U.S. Patent and Trademark Office,with claims directed to the use of oligonucleotide drugs to inhibittelomerase in patients. Telomerase inhibitors of this type, includingGRN163, are currently undergoing pre-clinical testing at Geron for usein treating a range of human cancers. "Geron was the first to clone the RNA component of humantelomerase," noted David J. Earp, J.D., Ph.D., Geron´s vice presidentof intellectual property, "and we have previously been granted patentsfor that RNA and oligonucleotide compounds based on its sequence. Thislatest patent is a significant addition to our portfolio because itexplicitly covers the use of those oligonucleotides to treat patients.The Patent Office sets a high hurdle for claims to methods of treatingpatients -- in this case we were able to submit data showing theefficacy of these oligonucleotides against a number of different typesof human tumors in animal models." GRN163 is a potent, specific and non-toxic inhibitor of telomerasein cancer cells. The drug is a short (13 base) oligonucleotide madeusing proprietary chemistry that confers stability and enhancedcellular uptake to the compound. The drug is active against all majorhuman tumor types in vitro and in animal models of human brain,prostate, lymphoma, myeloma and cervical cancers. Unlike mostanti-cancer drugs, GRN163 has not caused toxicity in animals attherapeutically effective doses. The compound is now undergoingIND-enabling GLP toxicology studies and, depending on results, thecompany expects to file an IND with the FDA for the treatment ofglioblastoma (brain cancer). Geron is a biopharmaceutical company focused on developing andcommercializing therapeutic and diagnostic products for applicationsin oncology and regenerative medicine, and research tools for drugdiscovery. Geron´s product development programs are based upon threepatented core technologies: telomerase, human embryonic stem cells andnuclear transfer. This news release may contain forward-looking statements madepursuant to the "safe harbor" provisions of the Private SecuritiesLitigation Reform Act of 1995. Investors are cautioned that suchforward-looking statements in this press release regarding futureapplications of Geron Corporation´s technology constituteforward-looking statements involving risks and uncertainties,including, without limitation, risks inherent in the development andcommercialization of potential products, need for additional capital,need for regulatory approvals or clearances, and the maintenance ofour intellectual property rights. Actual results may differ materiallyfrom the results anticipated in these forward-looking statements.Additional information on potential factors that could affect ourresults and other risks and uncertainties are detailed from time totime in Geron´s periodic reports, including the annual report on Form10-K for the year ended on December 31, 2002. --30--MCC/sf* CONTACT: Geron Corporation, Menlo Park David Greenwood, 650/473-7765 (Investor and Media Relations) KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY GOVERNMENTPRODUCT SOURCE: Geron Corporation |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | trojas (15.04.03 14:32:54) |
| Beitrag: | 85 von 3,090 (ID:9178184) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |